Clinical Trial – Becker muscular dystrophy study.
EDG-5506 was found to be well-tolerated without any serious adverse events reported.
EDG-5506 was found to be well-tolerated without any serious adverse events reported.
The drug is available orally with target engagement and anti-fibrotic effects in human fibrotic lung and kidney tissue.
The trial will evaluate multiple dose levels of AST-004 over six months at a clinical research site in Kistarcsa, Hungary.
Voxzogo improved height Z-score by 0.30 SD and annualised growth velocity by 0.92cm/year versus placebo.
The trial subjects had an overall response rate and complete response rate of 63% and 39%, respectively.
The trial will evaluate rivoceranib in 80 patients, including 53 based in the US.
This is a best prospect industry sector for this country. Includes a market overview and trade data.
The responsibility of the clinical trial monitor is to ensure that the trial is being conducted in accordance with ICH GCP guidelines.
Analysts at the Institute for Scientific Information report on the research profiles of 34 countries in South and Central America, Mexico and the Caribbean.
The trial will analyze the safety and efficacy of afuresertib plus fulvestrant combination in HR+/HER2- breast cancer patients.